Good Health is Your Greatest Wealth……Virgil
People who think obesity is caused by diet eat less food and those who think it's caused by a lack of exercise work out more. The problem is that people overestimate the amount of calories burned during exercise and underestimate calories in the food …
See all stories on this topic »
NEW YORK (AP) — Many women don’t need to be screened for cervical cancer after a hysterectomy, but a new study says most get the test anyway.
(Reuters) – An experimental drug to combat amyotrophic lateral sclerosis, commonly called Lou Gehrig's disease in the United States, failed to work in an important trial and Biogen Idec said it would stop development of the treatment. The drug, dexpramipexole, had shown promise and seemed to work against ALS in a mid-stage clinical trial in 2011, creating hope for patients suffering from the progressive, fatal disease, who currently have few options. Biogen shares, which rose 25 percent in 2012, fell 2 percent. …
PARIS (Reuters) – French health regulators are studying limiting the use of contraceptive pills that carry health risks and will stop reimbursing prescription costs of some types from March, after a woman sued drugmaker Bayer over alleged side-effects. An inquiry launched this week by the ANSM health regulator will review prescription practices by doctors, who it says may be over-prescribing higher-risk third and fourth-generation pills. …
LONDON (Reuters) – The Western world's first drug to fix faulty genes promises to transform the lives of patients with an ultra-rare disease that clogs their blood with fat. The only snag is the price. The gene therapy for lipoprotein lipase deficiency (LPLD), a hereditary disorder that raises the risk of potentially lethal inflammation of the pancreas, is likely to cost more than $1 million per patient when it goes on sale in Europe this summer. Rare or so-called orphan diseases are winning unprecedented attention from drug developers. …
(Reuters) – Abbott Laboratories’ Xience Xpedition heart stent was approved by U.S. health regulators and will be launched in the United States immediately, the company said on Thursday. Heart stents are tiny tubular devices that prop open diseased blood vessels after angioplasty. Abbott’s stent delivers a drug, everolimus, which helps keep the vessel from reclogging. Abbott competes with Medtronic Inc and Boston Scientific in the market for heart stents. (Reporting By Debra Sherman; editing by John Wallace)